Evommune, Inc. (EVMN): who owns it and who trades it
As of Nov 16, 2026, EVMN insiders reported 9 open-market sales worth $2.3M and 3 purchases worth $164K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Luis C. Pena (CEO), with $551K. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Evommune
From the latest filingsOverall: more buying than selling. Insiders mostly sold. Funds and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns EVMN
105 funds and institutions reported EVMN shares worth $465M at the end of Q2 2026, about 97% of the company. The largest holder is EQT Fund Management S.a r.l. with 14.7%.
Funds and institutions (13F) 97%Everyone else 3%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| EQT Fund Management S.a r.l. | 5.29M | 14.68% | $70.3M | +7% |
| Ra Capital Management, L.P. | 3.49M | 9.70% | $46.4M | No change |
| T. Rowe Price Associates | 1.94M | 5.39% | $25.8M | +73% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1.93M | 5.35% | $25.6M | No change |
| JPMorgan Chase & Co | 1.55M | 4.31% | $23.4M | New |
| Rtw Investments, LP | 1.50M | 4.17% | $20M | No change |
| Nan Fung Group Holdings Ltd | 1.44M | 4.00% | $19.2M | No change |
| Point72 Asset Management, L.P. | 1.44M | 3.98% | $19.1M | +3823% |
| Andera Partners | 1.39M | 3.86% | $18.5M | -27% |
| Eventide Asset Management, LLC | 1.21M | 3.36% | $16.1M | No change |
| Vestal Point Capital, LP | 1.00M | 2.78% | $13.3M | New |
| Jupiter Topco LLC | 896,700 | 2.49% | $11.9M | New |
| BlackRock, Inc. | 886,538 | 2.46% | $11.8M | +32% |
| Vanguard Capital Management LLC | 881,895 | 2.45% | $11.7M | +94% |
| Baker Bros. Advisors LP | 847,390 | 2.35% | $11.3M | No change |
| Defilade Capital Management, L.P. | 793,145 | 2.20% | $10.5M | +17% |
| American Century Companies Inc | 755,018 | 2.10% | $10M | +53% |
| Alyeska Investment Group, L.P. | 704,425 | 1.96% | $9.4M | -3% |
| Balyasny Asset Management L.P. | 457,015 | 1.27% | $6.1M | New |
| Velan Capital Investment Management LP | 451,255 | 1.25% | $6M | +1% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, EVMN insiders reported $164K of open-market purchases and $2.3M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jul 8, 2026 | Kyle Carver | CFO | Purchase | 1,000 | $13.26 | $13.3K | Form 4 |
| Jul 7, 2026 | Arthur S Kirsch | Director | Purchase | 10,000 | $13.30 | $133K | Form 4 |
| Jun 22, 2026 | Janice Suzann Drew | Chief of Dev. Operations | Sale | 20,000 | $22.63 | $453K | Form 4 |
| Jun 22, 2026 | Jeegar Pravinkumar Patel | Chief Scientific Officer | Sale | 1,488 | $22.50 | $33.5K | Form 4 |
| Jun 22, 2026 | Luis C. Pena | CEO | Sale | 7,438 | $22.71 | $169K | Form 4 |
| Jun 2, 2026 | David E Cohen | Director | Sale | 5,456 | $20.21 | $110K | Form 4 |
| Jun 2, 2026 | David E Cohen | Director | Sale | 600 | $21.38 | $12.8K | Form 4 |
| Jun 1, 2026 | Jeegar Pravinkumar Patel | Chief Scientific Officer | Sale | 16,687 | $22.74 | $379K | Form 4 |
| Jun 1, 2026 | Luis C. Pena | CEO | Sale | 16,787 | $22.74 | $382K | Form 4 |
| May 28, 2026 | Gregory S. Moss | Chief Business & Legal O | Sale | 14,223 | $22.83 | $325K | Form 4 |
| May 28, 2026 | Kyle Carver | CFO | Sale | 18,175 | $22.84 | $415K | Form 4 |
| Dec 19, 2025 | Robert Lorne Hopfner | Director | Purchase | 1,000 | $17.35 | $17.4K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Luis C. Pena | President & CEO, Director | – | $551K | Jun 22, 2026 |
| Janice Suzann Drew | Chief of Dev. Operations | – | $453K | Jun 22, 2026 |
| Kyle Carver | Chief Financial Officer | $13.3K | $415K | Jul 8, 2026 |
| Jeegar Pravinkumar Patel | Chief Scientific Officer | – | $413K | Jun 22, 2026 |
| Gregory S. Moss | Chief Business & Legal Officer | – | $325K | May 28, 2026 |
| Arthur S Kirsch | Director | $133K | – | Jul 7, 2026 |
| David E Cohen | Director | – | $123K | Jun 2, 2026 |
| Robert Lorne Hopfner | Director, 10% owner | $17.4K | – | Dec 19, 2025 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
EVMN short interest
Moderate short interest. 9.3% of EVMN shares are sold short: about 1 share in 11. Over the last 12 reports the number of shares short went up 9%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 3.39M EVMN shares were sold short, 9.3% of the shares outstanding, down 4.1% from the report before. At the average daily volume of 1.15M shares, buying them all back would take about 3.0 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 3.39M | 9.33% | -4% | 1.15M | 3.0 |
| Oct 15, 2026 | 3.53M | 9.74% | +22% | 1.03M | 3.4 |
| Sep 30, 2026 | 2.89M | 7.97% | +1% | 749,525 | 3.9 |
| Sep 15, 2026 | 2.88M | 7.93% | -34% | 866,637 | 3.3 |
| Aug 31, 2026 | 4.36M | 12.03% | -7% | 375,196 | 11.6 |
| Aug 14, 2026 | 4.70M | 12.94% | +5% | 571,993 | 8.2 |
| Jul 31, 2026 | 4.48M | 12.44% | +12% | 517,045 | 8.7 |
| Jul 15, 2026 | 4.02M | 11.15% | -16% | 1.10M | 3.7 |
| Jun 30, 2026 | 4.78M | 13.27% | +12% | 1.81M | 2.6 |
| Jun 15, 2026 | 4.27M | 11.85% | +7% | 451,728 | 9.4 |
| May 29, 2026 | 3.98M | 11.04% | +28% | 431,958 | 9.2 |
| May 15, 2026 | 3.10M | 8.60% | -5% | 433,380 | 7.2 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Evommune company events
Evommune filed 16 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 5, 2026.
- Nov 5, 2026AnnouncementShared information with investors. Filing
- Nov 4, 2026AgreementEvommune, Inc. entered into an Exclusive License Agreement with Hinova Pharmaceuticals Inc., a company incorporated in the People’s Republic of China. Filing
- Oct 1, 2026AnnouncementShared information with investors. Filing
- Sep 23, 2026AnnouncementShared information with investors. Filing
- Sep 15, 2026AnnouncementShared information with investors. Filing
- Sep 9, 2026AnnouncementThe Company issued a press release announcing top-line results from its randomized, double-blind, placebo controlled, dose-ranging Phase 2b trial evaluating the efficacy and safety of oral MRGPRX2 antagonist, EVO756, in adults with moderate-to-severe Atopic Dermatitis. Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- Jul 30, 2026AnnouncementShared information with investors. Filing
- Jun 29, 2026AnnouncementThe Company issued a press release announcing top-line results from its randomized, double-blind, placebo controlled, dose-ranging Phase 2b trial evaluating the efficacy and safety of oral MRGPRX2 antagonist, EVO756, in adults with moderate-to-severe chronic spontaneous urticaria. Filing
- Jun 2, 2026VoteReported shareholder vote results. Filing
- May 7, 2026ResultsReleased financial results. Filing
- Apr 13, 2026AnnouncementShared information with investors. Filing
- Mar 5, 2026ResultsReleased financial results. Filing
- Feb 13, 2026AgreementEvommune, Inc. entered into a Securities Purchase Agreement with certain investors pursuant to which the Company, in a private placement, agreed to issue and sell to the Investors an aggregate of 4,494,279 shares of the Company’s common stock, par value $0.0001 per share. Filing
- Feb 10, 2026AnnouncementShared information with investors. Filing
- Dec 11, 2025ResultsReleased financial results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Evommune financials
Famous investors that hold EVMN
3 of the 50 well-known investors we track reported holding EVMN in their latest 13F filing. The largest position is Steve Cohen's, worth $20.1M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Steve Cohen · Point72 Asset Management | Q3 2026 | 2.43M | $20.1M | 0.0% | +70% |
| Israel Englander · Millennium Management | Q3 2026 | 847,296 | $7M | 0.0% | New |
| Ken Griffin · Citadel Advisors | Q3 2026 | 379,729 | $3.1M | 0.0% | +3441% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named EVMN in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | T. Rowe Price Associates, Inc. | 13G/A | 2.3% |
| Nov 16, 2026 | Point72 Asset Management, L.P. | 13G/A | 6.7% |
| Nov 16, 2026 | T. Rowe Price Associates, Inc. | 13G/A | 2.3% |
| Nov 16, 2026 | Point72 Asset Management, L.P. | 13G/A | 6.7% |
| Nov 10, 2026 | RA Capital Management, L.P. | 13D/A | 8.5% |
| Nov 10, 2026 | RA Capital Management, L.P. | 13D/A | 8.5% |
Questions about Evommune, Inc. (EVMN) stock
Who owns the most EVMN stock?
The largest reported owner of Evommune, Inc. (EVMN) is EQT Fund Management S.a r.l., with 14.7% of the company. In total, 105 funds and institutions reported holding EVMN at the end of Q2 2026, together about 97% of the shares. See the largest owners.
Are EVMN insiders buying or selling?
In the last 12 months, EVMN insiders reported 3 open-market purchases worth $164K and 9 sales worth $2.3M. The latest trade was on Jul 8, 2026. See every trade.
What is the short interest in EVMN?
As of Oct 30, 2026, 3.39M EVMN shares were sold short, 9.3% of the shares outstanding, down 4.1% from the report before. At the average daily volume of 1.15M shares, buying them all back would take about 3.0 trading days (days to cover). See the history.
Which famous investors hold EVMN?
3 of the 50 well-known investors we track reported EVMN in their latest 13F filing, including Steve Cohen, Israel Englander, Ken Griffin. The largest position is worth $20.1M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.